Invitalia and Sanofi, a French pharmaceutical company with a strong presence in Italy, have signed a development contract to expand and upgrade the Anagni (Frosinone) plant. The agreement was signed by Domenico Arcuri, CEO of Invitalia, and Giuliano Redaelli, Chief Financial Officer of Sanofi Italia. The director of the Sanofi plant in Anagni, Alessandro Casu, was also present at the signing. The total investment is 47.3 million euros, of which 17.4 granted by Invitalia.
New machinery will be installed in the Lazio plant and a new line for freeze-dried sterile products will be created. The plants will also be modernized to make them compliant with the latest pharmaceutical manufacturing guidelines.
The investment also includes the launch of a research and development program for the application of new technologies in the fields of pharmaceuticals, microbiology and analytical chemistry, with the aim of improving the quality level of the drugs produced in the plant.
“Today's signing – says Domenico Arcuri, managing director of Invitalia – guarantees solidity, development and competitiveness to the Anagni plant, located in an area which, in recent times, has particularly suffered the employment repercussions of the crisis. The development contract has long been one of the government's main instruments for the development of the country and of the South in particular. So far, thanks to this significant facilitation measure, 1.82 billion euros have been invested in Italy, 950 million of which by foreign companies".
“
Thanks to the contribution of Invitalia - declares Alessandro Casu, director of the Sanofi plant in Anagni - we can make our plant even more competitive. The total investment will allow us to increase the site's production capacity and its energy efficiency, improving the performance of our flagship lines and attracting new productions from other Group sites, with positive effects for the territory of the Province of Frosinone”.
“We are very satisfied – comments Giuliano Redaelli, Chief Financial Officer of Sanofi in Italy – with the collaboration with Invitalia. As with our Scoppito site, thanks to the development contract we now have extra help to guarantee new technologies and process and product innovations for the Anagni plant, thus contributing to its sustainability over time. All this confirms how much Italy is able to present itself as a production base for the pharmaceutical industry in Europe”.
